🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Report from compassionate program in Italy. Upadacitinib in patients with difficult-to treat Crohn’s disease | Crohn's & Colitis 360 | Oxford Academic ⁦Cristina Bezzio⁩ ⁦Federica⁩ ⁦Edoardo Savarino⁩ ⁦Silvio Danese⁩ academic.oup.com/crohnscolitis3…

Outcomes After Dose Intensification of #Risankizumab for #Crohn’s Disease - Clinical Gastroenterology and Hepatology cghjournal.org/article/S1542-… 💊Dose⬆️of risa to q4w or q6w recaptured clin response for 64% of pts with LOR to q8w dosing 💊Dose⬆️of risa➡️clin remission for 45%

The best of #ECCO 2025 with the amazing Beatriz Gros we discussed #prediction #diet #mediterraneanmcdonalds #gutbrain #addapt And so much more!!! open.spotify.com/episode/081rkO…

Our study on how diet may regulate the gut phageome-bacteriome interaction relaying to a disease protection, #IBD, is freshly out at Gut Journal gut.bmj.com/content/early/…

Biologics and small molecules do not increase cancer risk in IBD, even in those with a history of cancer. Reassuring news for our IBD patients 👍💎 cghjournal.org/article/S1542-…

Hi friends from all over the world. We need your help in completing this Global IBD Survey by Lancet GIH ! Your insights matter !

Relevant for clinical practice and trials !! Biologic switch timing and risk of infection in patients with ulcerative colitis/Crohn's disease: a retrospective s… pubmed.ncbi.nlm.nih.gov/40204205/

⁉️ Checkpoint inhibitor colitis? Sure, you've heard of it - but do you know enough about it to TEACH it? 🤓 FG has your back! Here's all you need to know 👇 👇 👇 fg.bmj.com/content/early/… With thanks to the Authors: Aditi Kumar (Aditi Kumar), Hazem Alnatour, Gabriel

🏆 An FG favourite - how should you go about investigating abnormal liver blood tests in patients with inflammatory bowel disease? A MUST-READ for all post-graduates. 🧠 fg.bmj.com/content/15/6/5… With thanks to the Authors: Jennifer Amy Scott, Christopher Mysko, Huw Purssell and

#CGH4ALL CGH 📣 🎯PCABs (vonoprazan) are more potent than PPIs, but long-term safety data are lacking📈 ✅After 5 year, this study revealed that Vonoprazan does not increase malignant gastric mucosal changes in healed EE ✅Similar safety profile to lansoprazole 📚Read

New on Atomic IBD Six data-driven tactics that can really shift the outcome curve for Crohn’s & UC — from faster diagnosis to smart drug positioning. If you treat IBD in 2025, this playbook is for you.

Over a decade since I collaborated with world-class epidemiologist Gil Kaplan MD MPH and his team, here is our long awaited paper out in nature reporting for the first time evolution of #ibd across 4 stages Helmsley Charitable Trust IOIBD CUHK Medicine GIVES-21 nature.com/articles/s4158…

Honoured to be part of this global effort! This consensus sets a bold agenda for IBD research—rooted in equity, innovation, and collaboration across disciplines and borders. Proud to work alongside inspiring colleagues around the world. Nature Reviews Gastroenterology & Hepatology

#DDW2025 Bring back the porcelaine dishes ! Could #microplastic (MP) increase risk of #IBD across generations? #PLANET 🔺11 🤰🏻, 4 with Crohns 🔺MP detected in all 💩 during 3rd trimester 🔺Higher MP count correlated with FCP, indicative of intestinal inflammation

Informative presentation on the PIANO registry data from Arushi Kohli on Infant outcomes after Exposure to biologics/ immunomodulator. 👶🏻N=438 4-17 yrs follow-up ➡️44% c section (higher than National average due to active disease/Perianal disease). ➡️71% breast fed- no linked

Mild Crohn's disease to kick off day 2 Ryan Ungaro MD MS Approx 30% patients will present with mild Crohn's disease, of whom the majority will maintain a mild phenotype over time Mild activity and mild severity But some will progress, so it is important to keep a close eye. So

Fatigue and IBD - by Ailsa Hart Assessment • Fatigue assessment scale • FACIT score • VAS (0-10) Assessment checklist: inflammatory status, lab tests and screening for co-morbid conditions Then “Do you Sleep?” Is sleep interrupted by symptoms, or early waking due to

OBESITY AND IBD by Edward Loftus Obesity is a chronic inflammatory statue Adipose tissue is not biologically inert (TNFa, IL-6, IL-8, leptin, adiponectin) Postulated role in the pathogenesis of IBD Potential risk factor for adverse outcomes Trends in BMI among IBD patients at

IBD Treatment Paradigms: past, present and future by David T. Rubin, MD #DDW2025 What is a treatment paradigm? Established approaches and strategies used in medical care for specific diseases or conditions Involves a combination of therapies (surgery, medications and other interventions

Our letter published in Gut Journal comparing the 4 RCTs of anti-TNF withdrawal in #IBD in light of the EXIT trial. DrShahidaDin Taku Kobayashi Aaron Bancil Nikolas Plevris gut.bmj.com/cgi/rapidpdf/g…